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Epstein-Barr virus (EBV) is present in all cases of endemic Burkitt lymphoma (BL) but in few European/North American spo-
radic BLs. Gene expression arrays of sporadic tumors have defined a consensus BL profile within which tumors are classifiable as
“molecular BL” (mBL). Where endemic BLs fall relative to this profile remains unclear, since they not only carry EBV but also
display one of two different forms of virus latency. Here, we use early-passage BL cell lines from different tumors, and BL sub-
clones from a single tumor, to compare EBV-negative cells with EBV-positive cells displaying either classical latency I EBV infec-
tion (where EBNA1 is the only EBV antigen expressed from the wild-type EBV genome) orWp-restricted latency (where an
EBNA2 gene-deleted virus genome broadens antigen expression to include the EBNA3A, -3B, and -3C proteins and BHRF1). Ex-
pression arrays show that both types of endemic BL fall within the mBL classification. However, while EBV-negative and latency
I BLs show overlapping profiles, Wp-restricted BLs form a distinct subgroup, characterized by a detectable downregulation of
the germinal center (GC)-associated marker Bcl6 and upregulation of genes marking early plasmacytoid differentiation, notably
IRF4 and BLIMP1. Importantly, these same changes can be induced in EBV-negative or latency I BL cells by infection with an
EBNA2-knockout virus. Thus, we infer that the distinct gene profile ofWp-restricted BLs does not reflect differences in the iden-
tity of the tumor progenitor cell per se but differences imposed on a common progenitor by broadened EBV gene expression.
Burkitt lymphoma (BL) is a B cell malignancy whose character-istic epidemiologic, histologic, and cytogenetic features and
whose association with a B cell growth-transforming virus, the
Epstein-Barr virus (EBV), have made it an important model for
the study of human lymphomagenesis (1). The tumor occurs in a
high-incidence “endemic” form, which is restricted to equatorial
Africa and New Guinea and is consistently EBV positive, and in a
low- to intermediate-incidence “sporadic” form elsewhere, with
the EBV association falling as low as 10 to 15% in the lowest-
incidence areas (Europe and North America) (2). Irrespective of
geography or viral association, BL presents as a monomorphic
tumor with a very high proliferation index and a significant rate of
apoptotic cell death; the tumor cells are phenotypically CD10
CD77 Bcl2, reminiscent of germinal center (GC) centroblasts
(3). A unifying pathogenetic feature of all BLs is deregulation of
c-myc oncogene expression resulting from one of three chromo-
somal translocations, t(8:14), t(2:8), or t(8:22), which place a
c-myc allele into an immunoglobulin (Ig) heavy or light chain
locus (4, 5). While additional genetic changes are almost certainly
required to complete the malignant process (6, 7), the prime im-
portance of the c-myc translocation is clear from experiments
where forced expression of c-myc/Ig fusion gene constructs in
either human B cells in vitro (8) or mouse B cells in vivo (9, 10) has
converted those cells to a proliferating BL-like phenotype.
Despite these characteristic features, the boundary between
classical BL and other lymphomas can be blurred. Thus, outside
areas in which BL is endemic, some c-myc/Ig translocation-posi-
tive lymphomas are classified as “atypical BL” on the basis of sub-
tle differences in histologic appearance or immunophenotype
(11). In addition, among tumors histologically identified as dif-
fuse large B cell lymphomas (DLBCLs), a small number have BL-
like characteristics, in terms of either c-myc/Ig translocation or
immunophenotype, and are consequently difficult to distinguish
from classical BL. Since BL and DLBCL require different treat-
ment regimes, these concerns prompted two studies (12, 13)
which used gene expression profiling to define a molecular BL
(mBL) phenotype that would aid accurate diagnosis. Using 95%
similarity to a consensus mBL gene signature as the criterion, all
classical BLs and almost all atypical BLs displayed an mBL pheno-
type, as did some (but not all) rare DLBCLs with ambiguous fea-
tures. The mBL signature differed from that of typical DLBCLs by
relative upregulation of c-myc target genes and of a subset of genes
activated in GC cells but relative downregulation of other GC-
associated genes, as well as of NF-B target and major histocom-
patibility complex (MHC) class I genes (12, 13). Note that these
pioneering studies focused on only European and North Ameri-
can tumors, and so, although not specified, it is likely that very few
cases were EBV positive. Nevertheless, more recent work suggests
that endemic BL tumors are broadly similar to sporadic tumors in
gene expression profiles (14). Therefore, although individual
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Burkitt tumors may differ in precise secondary changes en route to
malignancy, they all converge on gene expression profiles that are
highly related and lie within the circumscribed mBL boundary.
Whether there are patterns within the mBL signature that distin-
guish precise pathways of BL pathogenesis remains to be deter-
mined.
We were motivated to address this point further following the
identification of two types of endemic BL which display different
patterns of EBV antigen expression and, by inference, arise by
different pathogenetic routes (15). From in vitro studies, EBV
growth transformation of normal B cells to permanent lympho-
blastoid cell lines (LCLs) involves the constitutive expression of
six virus-encoded nuclear antigens (EBNA1, -2, -3A, -3B, and -3C
and LP) and two latent membrane proteins (LMP1 and LMP2);
this is referred to as a latency III (Lat III) infection (16). In con-
trast, endemic BLs exhibit a more restricted pattern of antigen
expression (17–19). The majority of such tumors, the so-called
latency I BLs, carry a wild-type transformation-competent EBV
genome and express only the nuclear antigen EBNA1 from the
EBNA1-specific latent promoter Qp (20–22). However, around
15% of endemic tumors, the so-called Wp-restricted BLs, carry an
EBNA2 gene-deleted genome and express EBNA1, -3A, -3B, and
-3C and the viral Bcl2 homologue BHRF1 from the Wp latent
promoter (23–25). This distinction may be important clinically
since, based on cell line studies, Wp-restricted BLs are markedly
more resistant to apoptosis than are latency I BLs (24, 26) and may
therefore require more aggressive therapy. Despite their different
behavior in apoptosis assays, both types of tumor express c-myc at
high levels from a classically translocated allele and display typical
GC-like phenotypic markers (19, 23).
Given the existence of endemic BLs arising through two appar-
ently different pathogenetic routes, the present work set out to
address the following questions: (i) do both types of endemic tu-
mors show gene expression profiles within the mBL signature, (ii)
can their profiles be distinguished by subtle changes within that
signature, and (iii) if so, do such changes reflect differences in the
identity of the tumor progenitor cell per se or differences induced
in a common progenitor by the different forms of viral infection?
MATERIALS AND METHODS
Cell lines. BL2, BL30, and L3055 are EBV-negative sporadic BL lines (27).
Kem-BL, Rael-BL, and Wan-BL are endemic EBV-positive latency I BL
lines which express a single latent antigen, EBNA1 (19, 28). Tam-BL,
Tiaz-BL, and Tiyo-BL are endemic EBV-positive BL lines which have
drifted phenotypically during in vitro passage and now express the full
range of EBV latent antigens (latency III). Ava-BL, Awia-BL, Oku-BL, and
Sal-BL are Wp-restricted BL lines coinfected with wild-type and EBNA2-
deleted virus genomes (23, 26). The EBV-negative, latency I, and Wp-
restricted subclones of Awia-BL were generated by single-cell cloning as
described previously (26). Awia tr-LCL was made by inducing virus rep-
lication in the Awia-BL line and rescuing transforming virus by infection
of resting B cells (26). Standard BL lines and LCLs were maintained in
RPMI 1640 medium (Invitrogen) containing 10% (vol/vol) selected fetal
calf serum and 2 mM glutamine (Sigma). Wp-restricted BL lines were
grown in complete RPMI 1640 medium further supplemented with 1 mM
sodium pyruvate, 50 M alpha-thioglycerol, and 20 nM bathocupronine
disulfonic acid.
In vitro infection with EBNA2-deleted rEBV. The EBNA2-deleted
recombinant EBV (EBNA2 KO [E2KO] rEBV), derived from the wild-
type 2089 virus, was kindly provided by W. Hammerschmidt (29). EBNA2
KO rEBV stocks were generated from stably transfected HEK293 cells as
described previously (30). Awia-BL clones were infected with EBNA2 KO
rEBV at a multiplicity of infection (MOI) of 50, and EBV-converted cell
lines were generated following selection in medium containing 100g/ml
hygromycin.
Western blotting. Immunoblotting for EBV antigens and cellular
proteins was performed using the following monoclonal antibodies: 1H4
(anti-EBNA1) (31), PE2 (anti-EBNA2) (32), CS1-4 (anti-LMP1) (33),
5B11 (anti-BHRF1; Millipore, United Kingdom), H170 (anticalregulin;
Santa Cruz Biotechnology, CA), and C-8 (anti-c-Myc; Santa Cruz Bio-
technology, CA). EBNA3A was detected using a polyclonal antibody,
F115P (Exalpha Biologicals, Maynard, MA).
Real-time PCR analysis. Total RNA (400 ng) was reverse transcribed
using qScript cDNA Supermix (Quanta Biosciences) according to the
manufacturer’s instructions and then diluted to a final volume of 100 l.
TaqMan gene expression assays (Applied Biosystems, Foster City, CA)
were used to detect transcripts for Pax5 (Hs00172003), IRF4
(Hs00180031), Bcl6 (Hs00153368), Blimp1/PRDM1 (Hs00153357),
c-myc (Hs00153408), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (4310884E). Assays were performed in a 25-l reaction volume
containing 1 TaqMan Universal PCR master mix, 1.25l TaqMan gene
expression assay, 0.5 l GAPDH endogenous control assay, and 5 l di-
luted cDNA. Thermocycling and data collection were performed using an
Applied Biosystems 7500 real-time PCR system. All test samples were run
in triplicate, and template-negative and reverse transcriptase (RT)-nega-
tive samples were included as controls. Each run also contained 5-fold
serial dilutions of a reference cDNA which were used to construct a cali-
bration curve for each test gene. Raw data were analyzed using 7500 Sys-
tem Software v1.4, normalized to GAPDH expression, and then reported
relative to the reference cell line.
HGMP cDNA glass slide arrays. Dual-color microarray experiments
were performed essentially as described previously (34). Briefly, RNA was
extracted from BL cell lines using TRIzol and mRNA was subsequently
isolated with an Oligotex mRNA minikit (Qiagen, Crawley, United King-
dom), followed by DNase I digestion. Purified mRNA (1 g) was reverse
transcribed and labeled with Cy5 (CyScribe first-strand cDNA labeling
kit; GE Healthcare Life Sciences, United Kingdom). Cy5-labeled test
cDNA was then mixed 1:1 with Cy3-labeled reference cDNA (generated
from 6 cell lines in the following proportions: HeLa, 25%; HuH7, 20%;
Ramos, 15%; MRC5, 5%; LCL, 25%; U937, 10%). The Cy5/Cy3 mixes
were hybridized overnight to custom Human Genome Mapping Project
(HGMP) cDNA glass slide arrays (comprising approximately 5,700 hu-
man genes), washed, and dried. Finally, the slides were scanned using a
GenePix 4000B scanner (Axon Instruments, Union City, CA), the Cy5
and Cy3 fluorescence intensities were extracted for each gene spot, and the
data were exported as GenePix Result (GPR) files.
To analyze the HGMP array data, GPR files were first imported into
the CARMAweb analysis package (https://carmaweb.genome.tugraz.at
/carma/). Experimental features flagged as “bad” were removed along
with control elements, background fluorescence was subtracted using the
Normexp method (35), and log2 median and mean ratios for Cy5 and Cy3
signals/spot were calculated. Within-array normalization was performed
using the “robust splines” method, and between-array normalization was
performed using the “scale” method (36). The normalized data were then
exported and analyzed using TMEV (37). Briefly, the data structure was
grouped by average linkage hierarchical clustering using the Pearson
correlation coefficient as the distance metric and visualized using Java
TreeView (38). Based on the original BL classification, differentially ex-
pressed genes were identified using significance analysis of microarrays
(SAM) (39, 40) with an appropriate false discovery rate (FDR). In each
case, differentially expressed genes are clustered by average linkage hier-
archical clustering using the Pearson correlation coefficient.
Affymetrix HGU133 Plus 2.0 arrays. Gene expression profiling using
the Affymetrix Human Genome U133 (HGU133) Plus 2.0 arrays was
performed according to the Affymetrix protocol (Santa Clara, CA).
Briefly, biotinylated RNA was fragmented and hybridized to the gene
chips. After washing and staining using an Affymetrix FS450 fluidics sta-
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tion, arrays were scanned using a GeneChip 3000 7G scanner. GeneChip
Operating Software (GCOS) was used for instrument control and data
acquisition. Scanned images were analyzed using GCOS and Expression
Console software (Affymetrix), with the target signal set to 100. Ratios for
GAPDH and beta-actin (3=/5=) were within acceptable limits (GAPDH,
0.995 to 1.17; beta-actin, 1.31 to 2.02), and BioB spike controls were
present in all 12 chips, with BioC, BioD, and CreX also present in increas-
ing intensity. Scaling factors ranged from 1.03 to 5.08, background ranged
from 33 to 54, raw Q values ranged from 0.89 to 1.7, and percent present
ranged from 32.3% to 40.3%. Probe-level quantile normalization (41)
and robust multiarray analysis (42) on the raw CEL files were performed
using the Affymetrix package of the Bioconductor (http://www
.bioconductor.org) project. Differentially expressed probe sets were iden-
tified using SAM with the fold change threshold set to 1.5 and the FDR
(the Q value) below 1%. Gene expression heat maps were generated using
dChip (http://www.dchip.org). The sample correlation heat map was gen-
erated using the R gplots package.
The mBL phenotypes of eight Awia-BL clones (four latency I and four
Wp restricted) were compared against 60 reference primary tumors (30
mBLs and 30 DLBCLs) randomly selected from the Molecular Mecha-
nisms in Malignant Lymphoma (MMML) archive. Briefly, the raw
Awia-BL and MMML data sets were merged based on common probe
sequences between the HGU133 Plus 2.0 and HGU133A gene chips. Pre-
processing and add-on normalization were performed to allow direct
comparison of expression values (43). Expression values from the mBL
signature genes were then used to calculate a single representative value
(mBL index) for each sample by fitting a standard additive model with
independent gene and sample effects using Tukey’s median polish proce-
dure (44).
Microarray data accession number. The primary data are available
from NCBI’s Gene Expression Omnibus (GEO) (http://www.ncbi.nlm
.nih.gov/geo) under the GEO series accession number GSE42867.
RESULTS
Cellular gene expression profiling of BL cell lines with different
patterns of viral gene expression.The initial experiments focused
on cell lines established from three typical latency I BL lines and
three Wp-restricted BL lines, all of endemic (African) origin.
These were compared with three EBV-positive endemic BL lines
which, though established from conventional latency I tumors,
had switched during in vitro passage to a latency III pattern of viral
gene expression and acquired an LCL-like cell phenotype (18, 45),
and three EBV-negative sporadic BL lines. These different pat-
terns of latent antigen expression are illustrated in Fig. 1. Latency
I BL lines express EBNA1 only, while Wp-restricted BL lines ex-
press EBNA1, the EBNA3 family (here shown by EBNA3A), and
BHRF1; note that while BHRF1 is usually considered a lytic cycle
antigen (46), Wp-restricted BLs express BHRF1 as a latent protein
from the EBNA2 gene-deleted virus genome (24). In contrast, the
latency III-switched BL lines (and a representative tightly latent
LCL, X50-7) express the full spectrum of latent genes, including
the key markers of an EBV growth-transforming infection,
EBNA2 and LMP1; the low levels of BHRF1 in the latency III BL
lines reflect virus replication in a small fraction of cells. Impor-
tantly, latency I and Wp-restricted BL lines retain high-level ex-
pression of c-Myc, a key feature of the BL tumor, in contrast to the
lower c-Myc levels typically seen in LCLs and in latency III BL
lines.
We then compared the gene expression profiles of three BL
lines of each type using a custom cDNA glass slide array. Using a
set of 1,969 genes which passed our filtering criteria, both the
genes and samples from all 12 array experiments were first ordered
and then grouped by hierarchical clustering (Fig. 2A). The 12 in-
dividual lines clustered into two main branches. The first branch
contained the latency I lines (Kem-BL, Rael-BL, and Wan-BL), the
EBV-negative lines (L3055, BL2, and BL30), and the Wp-re-
stricted lines (Sal-BL, Oku-BL, and Ava-BL); note that the latency
I and EBV-negative lines were intermingled, whereas two Wp-
restricted lines formed a separate outgroup. In contrast, the la-
tency III lines (Tiyo-BL, Tiaz-BL, and Tam-BL) were grouped into
a second main branch, indicating that the gene expression profile
of these lines was clearly different from that of the other BL lines
tested.
Given the limited number of features on the HGMP array, we
could not conduct a comprehensive comparison of our data with
the Affymetrix-defined mBL signature. Nevertheless, the HGMP
arrays did yield information on 16 genes whose differential ex-
pression between BL and DLBCL defined the mBL signature (12,
13). We therefore used the HGMP array data to determine the
mean expression levels of those informative genes in the different
sets of BL lines. Figure 2B shows the results for eight genes re-
ported to be upregulated in BL relative to DLBCL. Of these, four
genes (TCF3, BMP7, APBB2, and HMGB1) were more highly ex-
pressed in EBV-negative and latency I BLs than in latency III lines;
in these four cases, levels of expression in Wp-restricted BLs were
either similar to those in the EBV negative/latency I subset or
intermediate between these subsets and the latency III values. In-
terestingly, the four remaining genes (CSE1L, TERT, RFC3, and
TFDP2) were equally expressed across all four BL subsets. Con-
FIG 1 Analysis of EBV antigen expression in BL lines. Expression of the viral
proteins EBNA1, EBNA2, EBNA3A, LMP1, and BHRF1 was detected by im-
munoblotting of cell lysates using the relevant specific antibodies. Calregulin
was used as a loading control. BL2 and BL30 are EBV-negative BL lines.
Rael-BL and Wan-BL are EBV-positive BL lines displaying a typical latency I
(Lat I) form of infection characterized by the expression of a single latent
antigen, EBNA1. Ava-BL and Sal-BL are Wp-restricted BL lines which express
EBNA1, EBNA3A (and EBNA-3B and -3C [not shown]), and BHRF1. Tiaz-BL
and Tiyo-BL are latency III BL lines which express the full spectrum of latent
antigens detected in EBV-transformed LCLs (here shown by the tightly latent
X50-7 LCL). Note that c-Myc protein is highly expressed in EBV-negative BL,
latency I BL, and Wp-restricted BL lines but is downregulated in latency III BLs
and the X50-7 LCL.
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versely, Fig. 2C shows the results for eight genes reported to be
downregulated in BL relative to DLBCL. Of these, six genes
(STAT3, CD44, NFKBIA, CRIP1, PIM2, and CCL3) showed lower
levels of expression, not just in the EBV-negative/latency I lines
but also in the Wp-restricted BLs, than in the latency III lines; the
other two genes (BCL2A1 and SQSTM1) were expressed at similar
levels in all four BL subsets. Overall, these findings provide pre-
liminary evidence that Wp-restricted BL lines, like the EBV-neg-
ative/latency I BLs, display an mBL-like gene expression profile
but may form a subtly distinct group of tumors within the mBL
classification. In contrast, the latency III BL gene expression pro-
file is clearly distinct from that of the other three BL subsets, al-
though latency III BL cells still retain some features of gene expres-
sion that are characteristic of their BL origin.
To search for differentially expressed genes which distin-
guished between the four BL subsets, we next carried out group-
wise comparisons using significance analysis of microarrays at ap-
propriate false discovery rates (Fig. 3A). Comparison of EBV-
negative/latency I with latency III BLs identified 94 statistically
significant genes (Fig. 3B); 16 genes upregulated in EBV-negative/
latency I lines and 78 upregulated in latency III lines. Many of the
latter have already been reported as features of the in vitro-trans-
formed LCL phenotype (47) and include genes known to be in-
duced either by EBNA2 (IFNGR1, CCL3L3, CD53, RUNX3, and
CASP1) (48, 49) or by LMP1 (the transcription factors JunB,
IRF7, and RUNX3; the NFKB-related factors NFKBIA and
TRAF1; CD58; CD95/FAS; and TNFAIP3/A20) (50). The mark-
edly different expression profile of latency III BLs emphasizes the
dramatic phenotypic change that occurs in those endemic BL cell
lines that, on serial passage, spontaneously switch from a c-myc-
driven to an EBV-driven growth program.
In contrast, there were far fewer differences between EBV-neg-
FIG 2 Gene expression profiling of BL cell lines using HGMP arrays. (A) Hierarchical clustering of EBV-negative (L3055, BL2, and BL30), latency I (Lat I)
(Kem-BL, Rael-BL, and Wan-BL), Wp-restricted (Sal-BL, Ava-BL, and Oku-BL), and latency III (Tiyo-BL, Tiaz-BL, and Tam-BL) BL lines using a filtered data
set of 1,969 genes. Each column represents one sample, and each row represents one gene. Gene expression is shown as a pseudocolored representation of log2
expression ratio, with yellow being above and blue being below the row’s median level of gene expression, as shown by the scale. The dendrogram relates samples
by the gene expression pattern, with shorter branch lengths indicating closer similarity. (B) Microarray expression data of selected mBL signature genes identified
by Hummel et al. (12) (TCF3, BMP7, APBB2, CSE1L, TERT, RFC3, and TFDP2) or Dave et al. (13) (TCF3, BMP7, HMGB1, RFC3, and TERT) as being
upregulated in BL relative to DLBCL. (C) Microarray expression data of selected mBL signature genes identified by Hummel et al. (12) (STAT3, CD44, NFKBIA,
CRIP1, BCL2A1, and SQSTM1) or Dave et al. (13) (STAT3, CD44, NFKBIA, BCL2A1, PIM2, and CCL3) as being downregulated in BL relative to DLBCL. In
panels B and C, the HGMP array data (two probe sets for each of the three cell lines in a BL subset) are represented as a box-and-whiskers plot, with each gene
expressed as a log2 expression ratio relative to the median.
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ative, latency I, and Wp-restricted BL lines (Fig. 3A). Comparison
of EBV-negative/latency I BLs with Wp-restricted BLs yielded
only 12 genes, while comparison of latency I BLs with Wp-re-
stricted BLs yielded 25 genes, including almost all of the previous
12. These 25 genes (18 upregulated and 7 downregulated in Wp-
restricted BL cells relative to latency I) are identified in Fig. 3C.
Searching among these 25 genes for candidates relevant to our
immediate purpose, namely, distinguishing between the two types
of tumor in terms of B cell phenotype, we identified two genes
encoding well-characterized markers of B cell differentiation:
Bcl6, a GC cell marker whose expression was higher in the latency
I lines, and Sub1 (PC4), a plasma cell differentiation marker
whose expression was higher in Wp-restricted lines. The positions
of these and other markers of the physiologic process of B cell
maturation from GC cell to plasma cell are summarized diagram-
matically in Fig. 4A.
Since many of these B cell differentiation markers were not
present on the original HGMP array, we used quantitative reverse
transcriptase PCR (RT-PCR) assays to compare the levels of Bcl6,
Pax5, IRF4, and Blimp1 transcripts in each of the relevant BL cell
lines (Fig. 4B). The expression of Bcl6 was indeed clearly highest in
latency I lines, lower in Wp-restricted lines, and lower still in the
latency III BL lines included for comparison; the data for Pax5
showed a similar but less dramatic trend. Conversely, IRF4 and
Blimp1 were both poorly expressed in latency I lines, were in-
creased in Wp-restricted lines (particularly with respect to IRF4),
and still higher in latency III lines. These findings reinforce the
earlier HGMP array data indicating that Wp-restricted BLs repre-
sent a subtly distinct subset of tumors within the mBL signature
and identify early changes on the GC-to-plasma cell differentia-
tion pathway as potential markers of that subset.
Cellular gene expressionprofilingofEBV-negative, latency I,
andWp-restricted clones derived from a single case of endemic
BL. Recognizing that at least some of the heterogeneity observed
FIG 3 Identification of differentially expressed genes in BL lines with different patterns of EBV latency. (A) Groupwise comparisons were performed to identify
differentially expressed genes using significance analysis of microarrays (SAM) at appropriate false discovery rates (FDRs). The comparisons included EBV
negative/latency I (Lat I) versus latency III, EBV negative/latency I versus Wp restricted, and latency I versus Wp restricted. The number of statistically significant
genes and the FDR for each analysis are indicated. Note that in the comparisons between EBV-negative/latency I and Wp-restricted lines, and between latency
I and Wp-restricted lines, it was necessary to use a much higher FDR of 10% to identify differences in gene expression. (B) Heat map of differentially expressed
genes between latency III and EBV-negative/latency I BL lines. In total, 78 genes were upregulated in latency III BLs, and 16 genes were upregulated in latency
I/EBV-negative BLs. EBNA2 target genes are shown in bold; LMP1 target genes are underlined. (C) Heat map of differentially expressed genes between latency
I and Wp-restricted BL lines. In panels B and C, differentially expressed genes were grouped by hierarchical clustering, with each column representing a cell line
and each row representing an individual gene. Gene expression is shown as a pseudocolored representation of log2 expression ratio relative to the row’s median
value, as shown by the scale. Gray indicates data removed by filtering.
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above is likely to arise through comparing individual tumors de-
rived from different patients, we next sought to move to an iso-
genic system. This became possible through our earlier identifica-
tion of a unique endemic tumor, Awia-BL, which was
heterogeneous in terms of EBV infection at the single-cell level. In
earlier work, we had single cell cloned the parental Awia-BL cell
line in early passage to generate EBV-negative, latency I, and Wp-
restricted clones all carrying the same t(8:14) translocation and a
unique trisomy 20 marker that confirmed their derivation from
the same malignancy (26). Confirmation that these different sets
of clones had the appropriate status with respect to EBV gene
expression was obtained by immunoblotting for virus-encoded
latent proteins (data not shown).
Representative Awia-BL clones of each type (duplicate cultures
of two independent EBV-negative clones, four independent la-
tency I clones, and four independent Wp-restricted clones) were
then subjected to gene expression profiling using Affymetrix U133
Plus 2.0 gene chips. First, we examined all the Awia-BL data sets
for expression of the 58 mBL signature genes (12). The resultant
heat map (Fig. 5A) shows data from latency I and Wp-restricted
Awia-BL clones alongside previously archived data from 30 refer-
ence cases of DLBCL and 30 reference cases of sporadic BL (12).
Clearly, all the Awia-BL clones, irrespective of latency pattern,
have gene expression profiles that fall within the boundary defin-
ing mBL. Indeed, for most of the 58 mBL signature genes, the
Awia-BL clones showed very closely related profiles, even sharing
particular exceptions to the general mBL signature (e.g., low ex-
pression of TUBB2A/2B). Note that idiosyncratic differences also
exist between individual reference BL tumors, even though all
these tumors are defined as BL through having gene expression
patterns that are95% similar to the consensus mBL profile. The
existence of such idiosyncratic differences emphasizes the impor-
tance to the present study of comparing EBV-negative, latency I,
and Wp-restricted BL cells all derived from the same tumor.
To search for relationships between the different Awia-BL
clones, we next arranged the cell lines according to the overall
similarity in their gene expression profiles. The results, illustrated
as a Pearson coefficient correlation matrix (Fig. 5B), show that the
four Wp-restricted clones form a tight homogeneous cluster sep-
arate from the other Awia-BL clones. By comparison, the EBV-
negative and latency I clones were more heterogeneous, with in-
dividual clones intermingled irrespective of their EBV genome
status. We then performed a SAM analysis to identify differentially
expressed genes which distinguish between Wp-restricted and la-
tency I Awia-BL clones. Of the 20,764 genes named on the
HGU133 Plus 2.0 array, 980 (4.72%) were significantly altered
between the two subsets; of these, 457 were upregulated and 523
were downregulated in Wp-restricted clones relative to latency I
(Fig. 6A).
To gain insights into the possible biological significance of
these changes, we used the web-based program DAVID (51) to
identify gene ontology (GO) terms associated with the top 200
upregulated and top 200 downregulated genes. We then com-
pared the GO term frequencies in these two gene lists with the
global GO term frequencies of all genes present on the array to
identify biological processes that are enriched in each gene list.
The results are summarized in Table 1 and depicted as heat maps
in Fig. 6B and C. Seven GO terms were overrepresented among the
200 upregulated genes, while four GO terms were overrepresented
in the 200 downregulated genes. Taken together, the most com-
mon terms were broadly linked to leukocyte activation, immune
system development, and regulation of developmental processes,
suggesting that subtle changes relating to B cell activation or dif-
ferentiation status are potential discriminators between Wp-re-
stricted BL and latency I BL lines.
To testthe earlier suggestion that changes on the GC-to-plasma
cell differentiation pathway were one such discriminator, we next
examined the overlap between these 980 differentially regulated
genes and a list of 2,877 genes previously reported to be differen-
tially expressed between plasma cells and germinal B centrocytes
(52). Of the 980 genes in our list, 259 (26.4%) were also differen-
tially expressed between plasma cells and centrocytes (odds ratio
[OR], 2.36; P  0.0000). Furthermore, there was a significant
overlap between genes upregulated in Wp-restricted BL and those
upregulated in plasma cells and likewise between genes down-
FIG 4 Expression of B cell differentiation genes in BL lines with different
patterns of EBV latency. (A) Schematic illustration of key transcription factors
involved in the transition from a germinal center to a plasma cell phenotype.
Briefly, this process is characterized by the activation of IRF4, which causes
upregulation of the master plasma cell regulator Blimp1/PRDM1 and down-
regulation of Bcl6, an inhibitor of plasma cell differentiation. Since Blimp1 and
Bcl6 form a double-negative inhibitory loop, increased levels of Blimp1 lead to
a further reduction in Bcl6 levels, reinforcing the switch from a GC to a plasma
cell phenotype. Plasma cell differentiation is also linked to loss of the pan-B-
cell marker Pax5 and upregulation of XBP1 (a positive regulator of plasma cell
differentiation). Sub1, which is activated in plasma cells, is a known IRF4 target
gene. (B) Quantitative RT-PCR analysis of Bcl6, Pax5, Blimp1, and IRF4 ex-
pression in latency I (Lat I), Wp-restricted, and latency III BL tumor subsets.
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FIG 5 Gene expression profiling of Awia-BL clones using HGU133 Plus 2.0 arrays. (A) Expression of mBL signature genes. The heat map shows the Affymetrix gene
expression levels for 58 mBL signature genes (74 probe sets) from 8 Awia-BL subclones (four each of latency I [Lat I] and Wp restricted) compared to 30 reference cases
of DLBCL and 30 reference cases of BL. Each column represents a different sample, and each row represents a different probe set (as indicated by the gene names on the
right side of the figure); blue and yellow indicate low and high levels of expression, respectively. In the heat map, samples were ordered according to their mBL index, with
the lowest value at the leftmost end of the figure. (B) Pearson correlation-based matrix of gene expression data sets from Awia-BL clones. The heat map shows a pairwise
correlation matrix for two EBV-negative clones (w and z, assayed in biological duplicate), four latency I clones (a, b, c, and d), and four Wp-restricted clones (m, n, p, and
q) based on Affymetrix gene expression data. The shading of each square represents the Pearson correlation coefficient, with red and blue indicating high and low
similarity, respectively.
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FIG 6 Identification of differentially expressed genes in Awia-BL clones. (A) Heat map representing differentially expressed genes between latency I (Lat I) and
Wp-restricted Awia-BL clones identified by SAM analysis using the criteria of1.5-fold change and 1% FDR. Each row in the heat map represents a gene, and
each column represents a sample. The expression levels for each gene were standardized to a mean value of 0 and a standard deviation of 1 and are represented
according to the color scale; red and green indicate high and low expression, respectively. (B and C) DAVID gene ontology analysis was used to identify enriched
genes (P  0.05, fold enrichment of 2) in the top 200 upregulated (B) or downregulated (C) transcripts, which were then grouped according to biological
function. (D) Comparison of differentially expressed genes with the plasma cell signature. The Venn diagrams show the overlap between genes significantly up-
or downregulated in Wp-restricted BL clones compared with latency I BL clones and genes up- or downregulated in plasma cells compared to centrocytes. The
HGU133 Plus 2.0 array contains 20,764 annotated genes, of which 980 are differentially expressed in Wp-restricted latency compared with latency I cells and
2,877 are differentially regulated in plasma cells compared to centrocytes; 259 genes are common to both data sets (odds ratio [OR], 2.36; chi-square, 136.2; P
0.0000). Four hundred fifty-seven genes are upregulated in Wp-restricted latency, of which 126 are concordantly upregulated in the plasma cell signature; thus,
genes which are upregulated in Wp-restricted latency are significantly enriched for genes increased during plasma cell differentiation (OR, 3.08; chi-square, 121.7;
P  0.0000). Conversely, 523 genes are downregulated in Wp-restricted latency versus latency I cells, of which 53 are concordantly regulated during plasma
differentiation; thus, genes which are downregulated in Wp-restricted latency are also significantly enriched for genes downregulated in the plasma cell signature
(OR, 4.75; chi-square, 127.1; P 0.0000).
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regulated in Wp-restricted BL and those downregulated in plasma
cells (Fig. 6D). Thus, the global analysis of gene expression in the
Awia-BL clones is consistent with a detectable shift from a GC
toward a plasmacytoid phenotype in Wp-restricted BL.
To further explore these findings, we screened our panel of
Awia-BL clones for the expression of key B cell differentiation-asso-
ciated genes both by RT-PCR and, where possible, by immunoblot-
ting for the relevant proteins. Representative data from two EBV-
negative, two latency I, and two Wp-restricted Awia-BL clones are
shown in Fig. 7, against parallel data from a standard LCL. We found
no consistent differences between the clones in the levels of Pax5
mRNA or protein. However, there was a tendency toward lower Bcl6
mRNA and protein levels in the Wp-restricted clones and a clear
increase in IRF4 and Blimp1 transcription (over the very low levels
detected in EBV-negative and latency I clones), accompanied by the
appearance of detectable IRF4 protein. However, these shifts toward
a more plasmacytoid phenotype in Wp-restricted clones were small
compared to the phenotype shown by LCLs, where Bcl6 expression is
fully extinguished while both IRF4 and Blimp1 are more strongly
expressed. Note also that the small changes seen in Wp-restricted
clones had occurred without prejudicing the high level of c-myc ex-
pression that was a characteristic of all the Awia-BL clones.
Recapitulating Wp-restricted infection in a BL cell back-
ground alters the cellular gene expression profile. In the final
experiments, we asked whether the shift toward a plasmacytoid
phenotype seen in Wp-restricted BLs had been imposed by this
form of EBV infection, rather than signifying that Wp-restricted
tumors had arisen from a progenitor cell at a slightly different
stage of differentiation. To do this, we took advantage of the fact
that the Wp-restricted form of latency can be generated in vitro by
infecting either EBV-negative or latency I BL cells with an EBNA2
gene-deleted (EBNA2 KO [E2KO]) virus. Thus, one EBV-nega-
tive Awia-BL clone and two latency I Awia-BL clones were in-
fected with a recombinant EBNA2 KO virus carrying a hygromy-
cin resistance gene, allowing selection of successfully infected
converts. As reported in earlier work (25), all such converts dis-
played a Wp-restricted form of latent gene expression from the
introduced recombinant EBV genome. When we compared these
E2KO-converted lines with their parent clones for expression of
key B cell differentiation-related genes (Fig. 8), we found that the
imposition of Wp-restricted latency did not affect Pax5 protein
expression but did lead to a clear reduction in Bcl6 protein in all
three E2KO converts. Furthermore, there was a significant up-
regulation of IRF4 and Blimp1 transcription, which was also
accompanied by increased IRF4 protein expression. For compar-
ison, we included E2KO and wild-type EBV converts of the EBV-
negative BL30 cell line. In the case of the E2KO convert, Bcl6
protein expression was clearly reduced compared to the parental
BL30 line, while the levels of IRF4 and Blimp1 were both markedly
increased. In contrast, Bcl6 expression was completely extin-
guished in the wild-type BL30 convert (which acquires a latency
III form of infection and an LCL-like phenotype), while IRF4 was
induced to even higher levels.
DISCUSSION
The difficulty of distinguishing between BL and certain cases of
DLBCL on purely histologic grounds prompted two landmark
studies defining a gene expression signature that was diagnostic of
BL (12, 13). However, that work was entirely based on BL present-
ing in its sporadic (low-incidence, predominantly EBV-negative)
form in Europe and North America. We were interested to extend
this type of analysis to the tumor in its endemic (high-incidence,
EBV-positive) form, particularly since we had identified two types
of endemic BL with different patterns of EBV latent gene expres-
sion (23, 25). Latency I tumors express just one EBV protein,
EBNA1, whereas Wp-restricted tumors express EBNA1, -3A, -3B,
and -3C plus the viral Bcl2 homologue BHRF1. In both cases, the
presence of EBV provides the tumor cells some protection from
apoptotic challenge (26); however, protection is much more
marked in Wp-restricted latency, implying that this particular
subset of tumors will be less responsive to standard chemotherapy
protocols. Since these two types of endemic BL appear to be his-
tologically identical, we investigated whether gene expression pro-
filing might distinguish between them. Here, we report that, while
both endemic BLs have gene expression profiles lying within the
mBL signature, Wp-restricted tumors form a transcriptionally
distinct subset characterized by subtle changes similar to those
seen when GC cells initiate differentiation toward a plasma cell
TABLE 1 GO analysis of differentially expressed genes between latency I and Wp-restricted Awia BL clones
Categorya Term Fold enrichmentb No. of genesc Fisher exactd
Top 200 upregulated genes
GO:0019882 Antigen processing and presentation 5.8 5 5.00E-03
GO:0045321 Leukocyte activation 3.5 10 5.50E-04
GO:0051094 Positive regulation of developmental process 3.4 11 4.20E-04
GO:0001775 Cell activation 3.0 10 2.00E-03
GO:0006955 Immune response 2.4 19 4.40E-04
GO:0044419 Interspecies interaction between organisms 2.4 9 1.80E-02
GO:0008219 Cell death 2.3 19 6.10E-04
Top 200 downregulated genes
GO:0002520 Immune system development 3.7 11 1.90E-04
GO:0030029 Actin filament-based process 2.7 7 1.40E-02
GO:0045321 Leukocyte activation 2.7 7 1.60E-02
GO:0050793 Regulation of developmental process 2.0 14 1.30E-02
a Gene ontology (GO) annotation.
b Fold enrichment of GO annotation term in top 200 up- or downregulated genes.
c Number of genes matching a GO annotation term.
d Fisher exact P value of gene enrichment.
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phenotype (52). Based on in vitro studies, we argue that the slightly
more differentiated phenotype of Wp-restricted BL does not re-
flect a different cell of origin for this tumor; rather, the changes in
gene expression are imposed on the classical mBL signature by the
novel Wp-restricted form of virus infection.
Out of necessity, we studied cell lines of endemic BL origin
rather than primary tumors. However, in most cases the cell lines
had been established in our own laboratory from fresh tumor
material and cryopreserved in early passage. While EBV-negative
sporadic BL lines tend to be phenotypically stable, latency I BL
lines fall into two groups: some are phenotypically stable over
multiple passages, and others (including many commonly used in
the literature) have switched toward an LCL phenotype with a
broadening of latent antigen expression (18, 19). We deliberately
selected three stable latency I BL lines and compared them with
three lines that had fully switched from Lat I to Lat III within the
first 20 in vitro passages. We then compared these with our unique
collection of three Wp-restricted lines, all in early passage; these
lines are also phenotypically stable and have since retained this
pattern of latency for50 passages.
Unsupervised analysis of data from the limited HGMP gene
array showed that the EBV-negative sporadic and both latency I
(Lat I) and Wp-restricted endemic BL lines clustered together and,
as far as could be tested, displayed expression profiles consistent
with the defined mBL phenotype. In contrast, the BL cell lines that
had switched to a latency III form of infection showed a quite
different profile, with multiple changes (Fig. 3B). Many of the
genes upregulated in these Lat III cells are diagnostic of a “B-
lymphoblastoid” or “activated B cell” phenotype involving, for
example, tumor necrosis factor receptor (TNFR) signaling com-
ponents, STAT signaling, cell surface adhesion molecules, and an-
tigen processing pathway components (53). Not surprisingly,
there are parallels with the expression profiles reported for con-
ventional LCLs and also that seen in a model B cell line when
switched from a c-myc-driven (BL-like) to an EBV-driven (LCL-
like) growth program (47). Many of these LCL-associated changes
have been assigned to the effects of two major effectors of the
EBV-induced transformation process, namely, EBNA2 as a tran-
scriptional activator (48, 54, 55) and LMP1 as an activator of the
NF-B pathway (50, 56). It is therefore worth noting that, as the
present study moves on to look for more subtle changes distin-
guishing between latency I and Wp-restricted BL lines, these two
forms of infection lack both EBNA2 and LMP1.
Both the HGMP array data on BL cell lines established from
different tumors and the Affymetrix data on clones established
from the Awia-BL tumor gave a consistent picture. In both cases,
gene expression profiling could not distinguish clearly between
EBV-negative and latency I BL cells (Fig. 2A and 5B). However, it
FIG 7 Expression of B cell differentiation genes in Awia-BL clones with different forms of latent infection. Two EBV-negative clones (w and z), two latency I (Lat
I) clones (a and d), and two Wp-restricted clones (m and n) of Awia-BL were screened for expression of key B cell differentiation markers. (A) Quantitative
RT-PCR analysis of Pax5, Bcl6, Blimp1, IRF4, and c-mycRNA expression. (B) Immunoblotting of Pax5, Bcl6, IRF4, and c-Myc protein expression; calregulin was
used as a loading control.
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was possible to distinguish between latency I and Wp-restricted
cells (Fig. 3C, 5B, and 6), even though both satisfied the criteria for
diagnosis as mBL (Fig. 5A). These differences within the mBL gene
signature are therefore subtle compared to the more dramatic
changes distinguishing mBL from DLBCL, or latency I from la-
tency III BL cell lines. We were interested to find that, in both types
of array (comparing latency I and Wp-restricted cells as BL lines or
Awia-BL clones), those subtle changes included genes linked to B
cell differentiation status. Focusing on those genes, we confirmed
that Wp-restricted BL cells are distinguished by a small but signif-
icant increase in the expression of genes such as IRF4 and Blimp1
that are linked with the early stages of GC cell-to-plasma cell tran-
sit, often accompanied by a reduction in the expression of genes
such as Bcl6 and Pax5 that are eventually suppressed in fully dif-
ferentiated plasma cells (Fig. 4B and 7).
We have argued in earlier work that the pathogenesis of latency
I and Wp-restricted BLs is likely to be subtly different (15). Thus,
the first involves a cell which (like most EBV-infected B cells in the
body) carries a wild-type transformation-competent EBV genome
that is capable of driving the proliferation of a preneoplastic clone;
in contrast, the second involves a precursor which carries a rare
EBNA2-deletion mutant that is growth transformation deficient.
Whether the different stages of differentiation displayed by la-
tency I and Wp-restricted BLs reflect a difference in precursor cell
identity is therefore an important issue to resolve. We approached
this by deliberately infecting EBV-negative and latency I clones of
the Awia-BL cell line with an engineered EBNA2-deletion mutant,
a procedure that we have previously shown stably establishes a
Wp-restricted form of infection (25). Gene-specific assays showed
that this led to a similar upregulation of IRF4 and Blimp1 and
downregulation of Bcl6 and Pax5, in the BL target cells (Fig. 8).
We therefore conclude that the subtly different phenotype of Wp-
restricted (compared to latency I) BL does not reflect its derivation
from a more differentiated precursor cell but rather a phenotype
that has been imposed upon a common BL precursor by an
EBNA2-deleted EBV genome. It remains to be seen what the viral
effectors of such a change are, the candidates being the EBNA3A,
-3B, and -3C and BHRF1 proteins and/or possibly the BHRF1
region-encoded microRNAs (miRNAs), all of which are expressed
in Wp-restricted but not in latency I BLs (23, 24, 57). Of these
candidates, one or more of the EBNA3 proteins appear to be the
most likely; thus, recent array data in a different system, looking at
BL cell lines which express all the EBV latent proteins except for
one or more EBNA3 family members, have noted some differ-
ences in B cell differentiation phenotype (58). However, we see
little overlap between the EBNA3-regulated genes identified in
that study and those in the present work (data not shown), per-
haps because the former was conducted on BL cells with an
EBNA2/LMP1-positive LCL-like phenotype and the latter on the
physiologic EBNA2/LMP1-negative BL background.
Regarding the cellular mutations which synergize with dereg-
ulated c-myc expression to clinch malignancy, two genomic stud-
ies have recently identified critical genetic changes in BL tumor
cells (6, 7). Strikingly, both studies reported frequent mutations in
the transcription factor TCF3 and its negative regulator ID3. In
collaboration with the Staudt laboratory, we recently reported the
ID3 and TCF3 mutation status in 10 of 13 BL lines studied in the
present work (6). Overall, 8 BL lines had missense or nonsense
ID3 mutations, while a single BL line had a TCF3 mutation. While
the numbers of cell lines examined in each category were only
small, the finding that ID3 is frequently mutated in both latency I
and Wp-restricted BL lines is consistent with the view that such
changes are common to the pathogenesis of both types of BL tu-
mor. However, further studies are required to fully elucidate the
phenotypic consequences of alterations in the ID3/TCF3 pathway
in these different BL settings.
The most important conclusion from the present work is that
two types of endemic BL, both with gene expression profiles that
fit within the mBL-defined boundary, nevertheless do show subtly
distinct phenotypes. They can best be distinguished by transcrip-
tional analysis using two marker genes, IRF4 and Blimp1, which
are not detectably expressed in latency I tumors but are activated
to easily detectable levels in Wp-restricted tumors. We believe that
such discrimination is important since, on the basis of in vitro
studies, Wp-restricted tumors are rendered much more resistant
to various apoptotic inducers, including cytotoxic drugs, than are
latency I tumors by virtue of expressing the viral Bcl2 homologue
BHRF1 (24, 59, 60). The prediction is that successful treatment of
this subset of endemic tumors will require more aggressive che-
motherapy, and so a means of identifying such tumors based on
their expression of key B cell differentiation genes could have sig-
nificant clinical benefit.
ACKNOWLEDGMENTS
This work was supported by a Cancer Research UK program grant (C910/
A8829) to A.B.R. and A.I.B. and a Kay Kendall Fellowship to G.L.K.
FIG 8 Analysis of Awia-BL clones converted with an EBNA2 KO rEBV. Two
latency I (Lat I) Awia-BL clones (a and d) and one EBV-negative Awia-BL
clone (z) were stably infected with a recombinant E2KO EBV and compared
with uninfected clones. (A) Quantitative RT-PCR analysis of IRF4 and Blimp1
RNA expression. (B) Immunoblotting of Pax5, Bcl6, and IRF4 protein expres-
sion; calregulin served as a loading control. EBV-negative BL30 cells and
matched E2KO and wild-type EBV converts were included as additional con-
trols.
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